BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial

BioAge Labs, Inc.

2025-Q3 EPS reported -$1.52 revenue$5,917,000

Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.
Cash, equivalents, and marketable securities $295.9M as of Sept 30, 2025, expected to fund operations through 2029.
First participant dosed in Phase 1 trial of oral NLRP3 inhibitor BGE-102; initial SAD data expected by year-end 2025.
Oral and parenteral APJ agonist programs on track for IND submissions in 2026; U.S. provisional patent filed May 2025.
Partnerships with Novartis and Lilly advancing as expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.